Latest XTL Biopharmaceuticals Ltd. Stories
HERZLIYA, Israel, June 1, 2011 /PRNewswire-FirstCall/ -- On May 29, 2011 XTL has announced that its rHuEPO (recombinant human erythropoietin) drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer. An orphan drug is defined as a drug treatment for an illness that affects a relatively small number of people in the population.
HERZLIYA, Israel, March 25, 2011 /PRNewswire-FirstCall/ -- - MinoGuard, a Private Biotechnology Company Developing Drugs for Mental Health Diseases, With its Lead Compound, SAM-101 for the Treatment of Schizophrenia; - MinoGuard Successfully Completed a 70 Patient Phase 2a Clinical Trial in Schizophrenia - use of the Drug Indicated Improvement of the Positive Symptoms of the Disease as well as Decrease of its Negative Symptoms XTL announced on March 24, 2011, it entered into a...
HERZLIYA, Israel, December 9, 2010 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
REHOVOT, Israel, April 16 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
REHOVOT, Israel, April 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.